Clinical Trials Logo

Methamphetamine Dependence clinical trials

View clinical trials related to Methamphetamine Dependence.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05283304 Terminated - Clinical trials for Methamphetamine-dependence

Monthly Injectable BUP for MA Use Disorder (MURB) Trial

CTN-0110
Start date: March 24, 2023
Phase: Phase 2
Study type: Interventional

This study is a 12-week randomized, double-blind, placebo-controlled trial that will investigate the use of injectable buprenorphine (BUP-Inj) compared to injectable placebo (PBO-Inj) for the treatment of methamphetamine use disorder (MUD) among individuals with mild co-use of opioids.

NCT ID: NCT05034874 Terminated - Clinical trials for Methamphetamine Abuse

Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200

OUTLAST
Start date: June 9, 2022
Phase: Phase 2
Study type: Interventional

This Phase 2 study will evaluate the safety and efficacy of monthly intravenous doses of IXT-m200 in treatment-seeking individuals with methamphetamine (METH) use disorder. The hypothesis are that following an initial relapse, IXT-m200 will reduce the occurrence of stimulant-positive saliva samples compared to placebo and improve the signs and symptoms of METH Use Disorder (MUD).

NCT ID: NCT01813656 Terminated - Clinical trials for Methamphetamine Dependence

An Study of Aripiprazole in the Treatment of Methamphetamine Dependence

Start date: September 2012
Phase: Phase 4
Study type: Interventional

Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. Aripiprazole are Second generation antipsychotics,but have different pharmacological effects of neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among mehtamphetamine addicts.

NCT ID: NCT01813643 Terminated - Clinical trials for Methamphetamine Dependence

A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis

Start date: July 2012
Phase: Phase 4
Study type: Interventional

Methamphetamine-associated psychosis (MAP) has been considered a pharmacological or environmental pathogen model of schizophrenia (SCZ) due in part to similarities in clinical presentation (i.e. paranoia, hallucinations, disorganized speech, and negative symptoms), response to treatment (e.g.neuroleptics),and pathologic mechanisms (e.g. central dopaminergic neurotransmission) of both conditions. Both risperidone and aripiprazole are second generation antipsychotics,but have different pharmacological effects of antipsychotic treatment.This study was designed to examine the acute efficacy, safety, and tolerability of risperidone and aripiprazole for patients with MAP.

NCT ID: NCT01019707 Terminated - Clinical trials for Methamphetamine Dependence

Safety Assessment of Atomoxetine With MA IV Administration

Start date: October 2009
Phase: Phase 1
Study type: Interventional

This is a study of 4 nontreatment seeking individuals who were MA-dependent and the safety and tolerability of atomoxetine. This double-blind, placebo-controlled, within-subjects study is to determine the safety and tolerability of atomoxetine. MA abusing participants will undergo a 1-day outpatient screening and if it is safe for the participants to proceed with the study they will participate in two inpatient components of the study that will occur in the University of California Los Angeles (UCLA) General Clinical Research Center (GCRC). The first inpatient stay will be 15 days, and the second will be a 9 days stay that includes drug administration and assessments. There will be at least a two week interval between inpatient components. During the inpatient components participants will receive alternating study drugs; atomoxetine or placebo and four sessions of IV MA administration or saline.

NCT ID: NCT00859573 Terminated - Clinical trials for Methamphetamine Dependence

Modafinil for Methamphetamine Dependence

Start date: April 2009
Phase: Phase 2
Study type: Interventional

Fifty methamphetamine dependent treatment-seeking volunteers will be enrolled in this 10 week, double bind, placebo controlled, randomized clinical trial to receive either modafinil or placebo. Eligible subjects will reside at the Recovery Centers of Arkansas residential facility to achieve initial abstinence and be inducted onto study medication during wks 1-2. Then during wks 3-10, subjects participate on an outpatient basis, receiving weekly psychotherapy while continuing to receive study medications. Urine samples will be collected thrice weekly and self reports weekly to assess methamphetamine use. It is hoped that the results of this study will contribute to our understanding of which types of agents may be good candidates for further development as potential treatment agents for this disorder.

NCT ID: NCT00730522 Terminated - Clinical trials for Methamphetamine Dependence

Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence

Start date: July 2008
Phase: Phase 2
Study type: Interventional

The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be methamphetamine-free in the last 2 weeks of the study's Treatment Phase (Weeks 11 and 12).

NCT ID: NCT00567866 Terminated - Clinical trials for Methamphetamine Dependence

Methamphetamine-Quetiapine Interactions in Humans

Start date: January 2008
Phase: Phase 0
Study type: Interventional

This study will test the ability of a medicine (Quetiapine) that is used to treat schizophrenia or bipolar disorder to reduce the effects of methamphetamine that make it difficult for users to stop using it. This study will test the ability of a medicine that is used to treat schizophrenia or bipolar disorder to reduce the effects of methamphetamine that make it difficult for users to stop using it. The investigator thinks quetiapine will lessen the effects of methamphetamine.